Career Opportunity

Regional Sales Manager (West)

Life Molecular Imaging (LMI) is a global, innovative R&D company focusing on the development and commercialization of molecular imaging radiopharmaceuticals for our approved F-18 amyloid PET tracer Neuraceq® and a pipeline of PET tracers in clinical development. LMI continues to grow at a steady pace creating the need for the following full-time position:

Regional Sales Manager (West)

Summary of Position:
The Regional Sales Manager is a mid-level manager who oversees the sales performance and strategy of a specific geographic area that aligns with the overall business goals and vision. Will be responsible for leading, coaching, and developing a team of sales representatives, as well as setting and tracking sales goals, budgets, and forecasts. This position will support the WestRegion, and the incumbent must live in the Central or Mountain time zones. The responsibilities below do not represent the entirety of the role but rather an overview of some of the key tasks.

 

Essential Responsibilities & Requirements (not all inclusive):

  • Design regional strategies to capitalize on sales opportunities and ensure that strategic plans complement marketplace needs. Defining and executing regional sales plans.
  • Identify and address operational bottlenecks and inefficiencies to improve workflow and productivity. Implement continuous improvement initiatives to enhance operational effectiveness.
  • Responsible for execution of effective commercial strategies in collaboration with senior management.
  • Overseeing and directing the performance of the sales team within region.
  • Evaluate, identify, and implement training and development plans for the sales team; working in coordination with internal or external partners as needed.
  • Track and analyze sales statistics based on key quantitative metrics. Make data-informed decisions to drive performance and resources.
  • 5-8 years of sales experience along with managerial responsibilities.
  • Knowledge of commercial issues associated with nuclear medicine, PET CT & neurology.
  • Exceptional leadership, communication, and analytical skills.
  • Experience leading a fully remote and dispersed workforce.
  • Demonstrated record of achieving and exceeding sales targets and increasing market share.

What we expect:
To be successful in this role, you must be able to manage working in a role with multiple time sensitive and pivoting priorities. You will need to be stress tolerant, highly organized, initiative-taking, flexible, and resourceful. A degree in business, sales marketing or related field is strongly preferred. Candidates must have 3-5 years of proven experience in planning, budgeting, leading & managing successful sales strategies. We are looking for people who are just as passionate as we are to improve the lives of those with Alzheimer’s and other neurodegenerative diseases.

What you can expect: 
A challenging and exciting career that is supported by coworkers, managers, and other departments within the company. You will be able to make significant contributions through your expertise and expect that what YOU do matters. You will be an integral part of a global organization, along with the communities we serve.

Life Molecular Imaging, Inc. is an Equal Opportunity Employer. We believe our company’s mission of “More Than a Job. It’s Making Life Better” extends to our culture of creating a welcoming, safe, and inclusive work environment. The salary range for this position is $140-160k. The specific salary offered to a candidate may be influenced by a variety of factors such as experience, education, and location. LMI offers a competitive benefit package including health, dental, vision, 401k and Life & Disability Insurances, and participation in the short-term incentive plans. If you have what it takes and the passion to make a difference, please visit our website to learn more at www.life-mi.com or apply here

Regional Sales Manager (West)
Neuraceq® - Product Indications And Use

PRODUCT INDICATIONS AND USE: Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.

Limitations: Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. The safety and effectiveness of Neuraceq have not been established for Predicting the development of dementia or other neurologic conditions or monitoring responses to therapies.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS

  • Risk for Image Misinterpretation and other Errors
    Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation [see Clinical Studies (14)]. Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future.
  • Radiation Risk
    Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration.

ADVERSE REACTIONS:

  • The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/appliucation site erythema (1.7%), injection site irritation (1.1%).

DRUG INTERACTIONS

  • Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Neuraceq image results.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: All radiopharmaceuticals, including Neuraceq, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Neuraceq administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.
  • Lactation: There are no data on the presence of florbetaben F 18 injection in human milk, the effects on the breastfed infant, or the effects of florbetaben F 18 injection on milk production. Exposure of Neuraceq to a breastfed infant can be minimized by temporary discontinuation of breastfeeding. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Neuraceq and any potential adverse effects on the breastfed child from Neuraceq or from the underlying maternal condition.
  • Pediatric Use: Neuraceq is not indicated for use in pediatric patients.
  • Geriatric Use: No overall differences in safety were observed between older and younger subjects

OVERDOSAGE
A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes. In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to Neuraceq administration, please read the full Prescribing Information for additional Important Safety Information.

SUSPECTED ADVERSE REACTIONS please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

.
.
.
.
.